News

Today we mark the World Bipolar Day, that is celebrated each year on March 30^th. Earlier this week we announced the launch of our EDIT-B test, the world’s first CE-marked in-vitro blood test designed to differentiate Bipolar Disorder from Depression.

EDIT-B is a biological and objective tool that complements the various existing clinical scales, whose interpretation is empirical. EDIT-B measures the RNA editing of specific markers in the blood of patients, advancing precision psychiatry innovation and bringing biology into psychiatric clinical routine.

Together with our partners in the EDIT-B consortium we stand for Mental Health and commit to making positive impact on the lives of people affected by Bipolar Disorder and their loved ones.

We would like to thank France Biotech for organising this ceremony. During this evening, 8 trophies were awarded to companies in the HealthTech sector, in the presence of Mr Roland Lescure, Minister Delegate in charge of Industry.

This award testifies to the recognition of ALCEDIAG by this French ecosystem and we thank France Biotech once again for making this possible.

Congratulations to all the nominees and to the other winners in all categories:

• HealthTech CSR: Algo Therapeutics
• Young company: Emobot
• HealthTech for Women: NORAKER
• Biotech: Orano Med
• MedTech: FineHeart
• Digital: I-VIRTUAL
• Favourites: Hemerion Therapeutics

La société française Alcediag et le réseau Synlab annoncent, à l’occasion du 31e congrès de l’EPA, la mise en place d’un partenariat pour la mise à disposition en Europe du test sanguin in-vitro marqué CE, EDIT-B, destiné à différencier le trouble bipolaire de la dépression majeure.

Read the article

PARIS and MILAN , March 27, 2023

• An estimated 2.3% of the European population is affected by bipolar disorder (BD)^[1], a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis^[2]
• To date, the diagnosis of BD is based on a psychiatric clinical examination of the patient, made by a psychiatrist.
• BD is so difficult to diagnose because it is often confused with depression. Misdiagnosed patients may receive inappropriate treatment, which may even worsen their health condition.
• To significantly reduce this diagnosis wondering, ALCEDIAG and SYNLAB are announcing, on the occasion of the 31^st EPA congress, the availability of EDIT-B™, the world's first CE-marked in-vitro blood test designed to differentiate BD from depression.

EDIT-B™: a reliable, validated and rapid biological response to reduce the diagnostic delay and address an unmet medical need. 

Download Press Release

ALCEDIAG is delighted to join this community of adherent companies. Thank you FranceBiotech for trusting us!

We share their mission which is the following: “For 25 years, France Biotech has been the voice of all entrepreneurs in biotechnology, medical technology and digital health. With the support of its expert partners, the members of the Bureau, the Board of Directors and the members of the commissions and working groups, France Biotech does everything possible to encourage and promote the development of HealthTech in France.”